News

Virginia Catalyst announces Grant Round 18 awarded teams

August 13, 2025  – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.4 million in grants to three life and bioscience projects in the Commonwealth of Virginia through a highly-competitive Grant Round 18.

 

“The bioscience ecosystem in Virginia is vibrant, with university researchers, incubator, accelerators, mentors, and VA Bio working together to drive economic development in the Commonwealth.” said Mike Grisham, CEO of Virginia Catalyst. “The Catalyst is proud to provide an avenue of non-diluted funding for these teams to further develop their innovations into commercialization in life sciences.”

 

Through this 18th round of funding, Virginia Catalyst has awarded 72 grants totaling over $38 million, resulting in nearly $56 million in matching funds and over $660 million in follow-on funding and 450 jobs in life sciences.

 

Grant Round 18 Awarded Teams

    

Ceres Nanosciences (Manassas), University of Virginia, and Virginia Tech

  • Awarded: $800,000
  • “Nanotrap® SECURE (Sample Enrichment Concentration Universal RNA/DNA Extraction) Kit”

 

HTIC, Inc. (Charlottesville), University of Virginia, and Virginia Commonwealth University

  • Awarded: $800,000
  • “Developing a first-in-class humanized monoclonal antibody for immune modulation in human diseases”

  

RIVANNA Medical, Inc. (Charlottesville), University of Virginia, and Virginia Commonwealth University

  • Awarded: $800,000
  • “Transforming epidural placement with precision-guided technology to enhance safety and patient satisfaction”

 

 

Read more here.

 

Recent News

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …

10/26/2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …